Lung cancer

IntegraGen is developing a molecular test based on the biomarker hsa-miR-31-3p, a microRNA whose expression has been correlated with the effect of EGFR TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) in patients with advanced non-small cell lung cancer (NSCLC).

Lung cancer is the most common form of cancer worldwide with approximately 1.8 million cases diagnosed on an annual basis. It is also the leading cause of cancer-related mortality being responsible for nearly one in five cancer-related deaths.

integragen-research-lung-cancer